Subject(s)
Antidepressive Agents/administration & dosage , Depressive Disorder/drug therapy , Drugs, Generic/adverse effects , Adult , Antidepressive Agents/economics , Antidepressive Agents/pharmacology , Cost Savings , Depressive Disorder/diagnosis , Drugs, Generic/administration & dosage , Drugs, Generic/economics , Family Practice , Female , Follow-Up Studies , Humans , Male , Middle Aged , Recurrence , Risk Assessment , Severity of Illness Index , Treatment OutcomeSubject(s)
Phobic Disorders/diagnosis , Shyness , Social Behavior Disorders/diagnosis , Anticonvulsants/administration & dosage , Antidepressive Agents/administration & dosage , Benzodiazepines/administration & dosage , Child , Cognitive Behavioral Therapy , Humans , Interpersonal Relations , Phobic Disorders/drug therapy , Phobic Disorders/therapy , Selective Serotonin Reuptake Inhibitors/administration & dosage , Social Behavior Disorders/drug therapy , Social Behavior Disorders/therapyABSTRACT
Dietary supplement use is widespread in developed nations. In particular, patients who utilize mental health services also report frequent consumption of dietary supplements, often in relation to management of adverse events and specifically weight gain. Weight gain induced by psychotropic medications can further compound psychological distress and negatively influence compliance. Here we report on four cases of social anxiety disorder treated with the atypical antipsychotic quetiapine. Self-administration of conjugated linoleic acid and green tea extract may have influenced objective anthropomorphic measurements; each patient had an unexpected decrease in total body fat mass, a decrease in body fat percentage and an increase in lean body mass. Since weight gain is a common and undesirable side-effect with psychiatric medications, our observation strongly suggests the need for controlled clinical trials using these agents.
Subject(s)
Catechin/analogs & derivatives , Dibenzothiazepines/pharmacology , Linoleic Acids, Conjugated/pharmacology , Psychotropic Drugs/adverse effects , Tea/chemistry , Weight Gain/drug effects , Adult , Body Fat Distribution , Catechin/pharmacology , Female , Humans , Male , Psychotropic Drugs/therapeutic use , Quetiapine Fumarate , ThinnessABSTRACT
Venlafaxine XR is a novel, dual acting SNRI antidepressant, which inhibits both serotonin and norepinephrine reuptake. Controlled trials have demonstrated the efficacy and safety of venlafaxine in the treatment of panic disorder. Generally well tolerated, with side-effects that usually abate with continued treatment, venlafaxine is an important option to the SSRIs for the treatment of patients with panic disorder.
